Increased Risk of Myelotoxicity in Elderly Patients with Non-Hodgkin Lymphoma: The Case for Routine Prophylaxis with Colony-Stimulating Factor Beginning in the First Cycle of Chemotherapy

Cancer

Volumn 100, Issue 1, 2004, Pages 6-11

  Balducci, Lodovico ^a   Repetto, Lazzaro ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Ist Naz Riposo e Cura per Anziani   (Italy)

Author keywords

Chemotherapy; Colony stimulating factor (CSF); Elderly; Myelotoxicity; Neutropenia; Non Hodgkin lymphoma (NHL)

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PIRARUBICIN; PREDNIMUSTINE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

AGED; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG FATALITY; ELDERLY CARE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

AGED; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONY-STIMULATING FACTORS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; NEUTROPENIA; PATIENT SELECTION;

EID: 0348108291     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11861     Document Type: Review

References (36)

1. Edwards BK, Howe HL, Ries LAG, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766-2792.
2. Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000;14:17-23.
3. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control. 2001;8(2 Suppl):1-25; quiz, 27-28.
4. Zelenetz AD, Reider PA, Delgado DJ. Review of patterns of care among community physicians in intermediate grade NHL (IGL) reveals significantly greater planned and delivered dose attenuation in older patients [abstract 588]. Blood. 2000;96:137a.
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.
6. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90:1205-1211.
7. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
8. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer. 1990;66:1124-1129.
9. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977.
10. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 1993;4:651-656.
11. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-2953.
12. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkins lymphoma (NHL). Ann Oncol. 1994;5:895-900.
13. Björkholm M, Ösby E, Hagberg H, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma [abstract 2655]. Blood. 1999;94:599a.
14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
15. Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065-2069.
16. O'Reilly SE, Connors JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol. 1993;11:2250-2257.
17. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530-2539.
18. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27-34.
19. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol. 1994;5(Suppl 2):127-132.
20. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89:3974-3979.
21. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999;94:33-38.
22. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of first febrile neutropenia (FN) among patients receiving CHOP chemotherapy [abstract 1430]. Proc Am Soc Clin Oncol. 2002;21:358a.
23. Caggiano V, Stolshek B, Delgado D, Carter W. First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkins lymphoma (IGL) patients on standard-dose CHOP therapy [abstract 1810]. Blood. 2001;98:431a
24. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47-56.
25. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857-1864.
26. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377-384.
27. Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:2386-2393.
28. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
29. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29-35.
30. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage IlI/IV breast cancer. J Clin Oncol. 2002;20:727-731.
31. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-324.
32. Gregory SA, Case DC Jr., Bosserman L, et al. 14 day CHOP in patients with aggressive non-Hodgkin's lymphoma (NHL): preliminary results [abstract 49]. Proc Am Soc Clin Oncol. 2000;19:15a.
33. Moore TD, Patel T, Segal ML, et al. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with NHL [abstract 2245]. Blood. 2002;100:571a.
34. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt). 2000;14:221-227.
35. Repetto L, Carreca I, Maraninchi D, Aapro M, Calabresi P, Balducci L. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol. 2003;45:123-128.
36. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558-3585.